In the past, SPRED2 has been linked to drug resistance [80] and described as a potential prognostic marker for multiple cancer types such as chronic myeloid leukemia [80,81], prostate cancer [66], and hepatocellular carcinoma [82]. This evidence concerns the gene SPRED2 and chronic myelogenous leukemia, BCR-ABL1 positive.